UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 60-70

  de Almagro, M Cristina ^a   Selga, Elisabet ^a   Thibaut, Rémi ^b   Porte, Cinta ^b   Noé, Véronique ^a   Ciudad, Carlos J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

Author keywords

Breast cancer; Drug resistance; Methotrexate; Microarray; UGT1A6

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A5; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLYCOSYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1; IRINOTECAN; ISOPROTEIN; LUCIFERASE; MESSENGER RNA; METHOTREXATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG GLUCURONIDATION; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; METHOTREXATE; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 78549245477     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.008     Document Type: Article

References (58)

1. Mayo C. [] 05/15/2010. http://wwwmayocliniccom/.
2. Chu E., Grem J.L., Johnston P.G., Allegra C.J. New concepts for the development and use of antifolates. Stem Cells 1996, 14:41-46.
3. Gorlick R., Goker E., Trippett T., Steinherz P., Elisseyeff Y., Mazumdar M., et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997, 89:1013-1018.
4. Blakley R.L., Cocco L. Dismutation of dihydrofolate by dihydrofolate reductase. Biochemistry 1984, 23:2377-2383.
5. Nagar S., Remmel R.P. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006, 25:1659-1672.
6. Burchell B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am J Pharmacogenom 2003, 3:37-52.
7. Mackenzie P.I., Owens I.S., Burchell B., Bock K.W., Bairoch A., Belanger A., et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997, 7:255-269.
8. Gong Q.H., Cho J.W., Huang T., Potter C., Gholami N., Basu N.K., et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001, 11:357-368.
9. Clarke D.J., Cassidy A.J., See C.G., Povey S., Burchell B. Cloning of the human UGT1 gene complex in yeast artificial chromosomes: novel aspects of gene structure and subchromosomal mapping to 2q37. Biochem Soc Trans 1997, 25:S562.
10. Nagar S., Blanchard R.L. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 2006, 38:393-409.
11. Burchell B., Brierley C.H., Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995, 57:1819-1831.
12. Ciotti M., Owens I.S. Evidence for overlapping active sites for 17 alpha-ethynlestradiol and bilirubin in the human major bilirubin UDPglucuronosyltransferase. Biochemistry 1996, 35:10119-10124.
13. Auyeung D.J., Kessler F.K., Ritter J.K. An alternative promoter contributes to tissue- and inducer-specific expression of the rat UDP-glucuronosyltransferase 1A6 gene. Toxicol Appl Pharmacol 2001, 174:60-68.
14. Munzel P.A., Lehmkoster T., Bruck M., Ritter J.K., Bock K.W. Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6. Arch Biochem Biophys 1998, 350:72-78.
15. Bock K.W., Kohle C. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 2005, 400:57-75.
16. Selga E., Noe V., Ciudad C.J. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 2008, 75:414-426.
17. Chasin L. The dihydrofolate reductase locus. Mol Cell Genet 1985, 449-488.
18. Omnibus GE. 05/15/2010. http://wwwncbinlmnihgov/geo/.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
20. Thibaut R., Schnell S., Porte C. Assessment of metabolic capabilities of PLHC-1 and RTL-W1 fish liver cell lines. Cell Biol Toxicol 2009, 25:611-622.
21. Ciudad C.J., Morris A.E., Jeng C., Chasin L.A. Point mutational analysis of the hamster dihydrofolate reductase minimum promoter. J Biol Chem 1992, 267:3650-3656.
22. Noe V., Alemany C., Nicolas M., Ciudad C.J. Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA)-mediated increase in resistance to methotrexate in Chinese hamster ovary cells. Eur J Biochem 2001, 268:3163-3173.
23. Selga E., Oleaga C., Ramirez S., de Almagro M.C., Noe V., Ciudad C.J. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med 2009, 1:83.
24. Krishnaswamy S., Hao Q., Al-Rohaimi A., Hesse L.M., von Moltke L.L., Greenblatt D.J., et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther 2005, 313:1331-1339.
25. Court M.H. Acetaminophen UDP-glucuronosyltransferase in ferrets: species and gender differences, and sequence analysis of ferret UGT1A6. J Vet Pharmacol Ther 2001, 24:415-422.
26. Ethell B.T., Anderson G.D., Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003, 65:1441-1449.
27. Krishnaswamy S., Duan S.X., Von Moltke L.L., Greenblatt D.J., Court M.H. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 2003, 31:133-139.
28. Krishnaswamy S., Hao Q., Von Moltke L.L., Greenblatt D.J., Court M.H. Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab Dispos 2004, 32:862-869.
29. Liu X., Tam V.H., Hu M. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm 2007, 4:873-882.
30. Wang M., Li Y.Q., Zhong N., Chen J., Xu X.Q., Yuan M.B. Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancel cells. Zhonghua Yi Xue Za Zhi 2005, 85:819-824.
31. Heurtaux T., Benani A., Moulin D., Muller N., Netter P., Minn A. Induction of UGT1A6 isoform by inflammatory conditions in rat astrocytes. Neuropharmacology 2006, 50:317-328.
32. Emi Y., Ikushiro S., Iyanagi T. Drug-responsive and tissue-specific alternative expression of multiple first exons in rat UDP-glucuronosyltransferase family 1 (UGT1) gene complex. J Biochem 1995, 117:392-399.
33. Grams B., Harms A., Braun S., Strassburg C.P., Manns M.P., Obermayer-Straub P. Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch Biochem Biophys 2000, 377:255-265.
34. Munzel P.A., Bookjans G., Mehner G., Lehmkoster T., Bock K.W. Tissue-specific 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human UDP-glucuronosyltransferase UGT1A6. Arch Biochem Biophys 1996, 335:205-210.
35. Yokota H., Ohgiya N., Ishihara G., Ohta K., Yuasa A. Purification and properties of UDP-glucuronyltransferase from kidney microsomes of beta-naphthoflavone-treated rat. J Biochem 1989, 106:248-252.
36. Buetler T.M., Gallagher E.P., Wang C., Stahl D.L., Hayes J.D., Eaton D.L. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 1995, 135:45-57.
37. Grove A.D., Kessler F.K., Metz R.P., Ritter J.K. Identification of a rat oltipraz-inducible UDP-glucuronosyltransferase (UGT1A7) with activity towards benzo(a)pyrene-7,8-dihydrodiol. J Biol Chem 1997, 272:1621-1627.
38. Kessler F.K., Ritter J.K. Induction of a rat liver benzo[a]pyrene-trans-7,8-dihydrodiol glucuronidating activity by oltipraz and beta-naphthoflavone. Carcinogenesis 1997, 18:107-114.
39. van de Kerkhof E.G., de Graaf I.A., Ungell A.L., Groothuis G.M. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 2008, 36:604-613.
40. Sugatani J., Kojima H., Ueda A., Kakizaki S., Yoshinari K., Gong Q.H., et al. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001, 33:1232-1238.
41. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P., Negishi Y., Bottroff B.S., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003, 100:4150-4155.
42. Barbier O., Villeneuve L., Bocher V., Fontaine C., Torra I.P., Duhem C., et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 2003, 278:13975-13983.
43. Yeager R.L., Reisman S.A., Aleksunes L.M., Klaassen C.D. Introducing the "TCDD-inducible AhR-Nrf2 gene battery" Toxicol Sci 2009, 111:238-246.
44. Emi Y., Ikushiro S., Iyanagi T. Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex. J Biol Chem 1996, 271:3952-3958.
45. Bock-Hennig B.S., Kohle C., Nill K., Bock K.W. Influence of t-butylhydroquinone and beta-naphthoflavone on formation and transport of 4-methylumbelliferone glucuronide in Caco-2/TC-7 cell monolayers. Biochem Pharmacol 2002, 63:123-128.
46. Auyeung D.J., Kessler F.K., Ritter J.K. Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the Aryl hydrocarbon receptor pathway. Mol Pharmacol 2003, 63:119-127.
47. Jemnitz K., Veres Z., Vereczkey L. Coordinate regulation of UDP-glucuronosyltransferase UGT1A6 induction by 3-methylcholanthrene and multidrug resistance protein MRP2 expression by dexamethasone in primary rat hepatocytes. Biochem Pharmacol 2002, 63:2137-2144.
48. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., Wrighton S.A. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004, 32:140-148.
49. Carver L.A., LaPres J.J., Jain S., Dunham E.E., Bradfield C.A. Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem 1998, 273:33580-33587.
50. Kress S., Greenlee W.F. Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 1997, 57:1264-1269.
51. Klinge C.M., Jernigan S.C., Risinger K.E., Lee J.E., Tyulmenkov V.V., Falkner K.C., et al. Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT). Arch Biochem Biophys 2001, 390:64-70.
52. Bock K.W., Bock-Hennig B.S. UDP-glucuronosyltransferases (UGTs): from purification of Ah-receptor-inducible UGT1A6 to coordinate regulation of subsets of CYPs, UGTs, and ABC transporters by nuclear receptors. Drug Metab Rev 2009.
53. Li J., Shi M., Cao Y., Yuan W., Pang T., Li B., et al. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 2006, 342:1341-1351.
54. Generali D., Berruti A., Brizzi M.P., Campo L., Bonardi S., Wigfield S., et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12:4562-4568.
55. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24:2875-2889.
56. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003, 17:503-505.
57. Gessner T., Vaughan L.A., Beehler B.C., Bartels C.J., Baker R.M. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res 1990, 50:3921-3927.
58. Franklin T.J., Jacobs V., Jones G., Ple P., Bruneau P. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 1996, 56:984-987.